A small pharmaceutical company on the brink of Nasdaq delisting pulled off a remarkable turnaround in just two months—celebrating new cancer treatment patents before abruptly rebranding as an AI company. The pivot provided a temporary boost to its share price, highlighting the market's appetite for anything AI-related.

The case illustrates how the AI boom is prompting desperate companies to reinvent themselves to attract investor interest. Small-cap stocks with little connection to artificial intelligence are attempting to capitalize on the sector's momentum, often with limited substance behind the rebrandings. Analysts have described the phenomenon as "peak euphoria" in the market.

Investors should approach such transformations with caution. The temporary stock price surge often masks underlying business challenges, and genuine AI capabilities require substantial technological infrastructure and expertise that cannot be quickly fabricated. The pattern suggests increased scrutiny from regulators and investors may follow.